This is a list of all the questions and their associated study carrel identifiers. One can learn a lot of the "aboutness" of a text simply by reading the questions.
| identifier | question |
|---|---|
| cord-277603-hpn1ovgo | COVID-19 pneumonia: different respiratory treatments for different phenotypes? |
| cord-290712-flj352ql | Prior COVID-19 Infection? |
| cord-299679-6z9e5gi6 | COVID-19 pneumonia different respiratory treatment for different phenotypes? |
| cord-285897-ahysay2l | China A pneumonia outbreak associated with a new coronavirus of probable bat origin Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? |
| cord-259453-1njd0c0x | Abnormal pulmonary function in COVID-19 patients at time of hospital discharge Pulmonary fibrosis secondary to COVID-19: a call to arms? |
| cord-259453-1njd0c0x | COVID-19 pneumonia: a random association? |
| cord-296440-18vpg419 | enquête Do chronic respiratory diseases or their treatment affect the risk of SARS- CoV-2 infection? |
| cord-290490-u3mkfvxw | Clinical considerations and technical tips Coronavirus Disease 2019( COVID-19): Role of Chest CT in Diagnosis and Management Galactomannan in bronchoalveolar lavage fluid: a tool for diagnosing aspergillosis in intensive care unit patients Azole resistance in Aspergillus fumigatus: a side- effect of environmental fungicide use? |
| cord-290080-hxte1gc1 | In their correspondence, the Authors raised two important issues, namely the possible association between tuberculosis( TB) and COVID-19( can infection by SARS- CoV-2 reactivate TB?) |
| cord-012010-5h2ox3hu | COVID-19 phenotypes: leading or misleading? |
| cord-012010-5h2ox3hu | COVID-19 pneumonia: different respiratory treatments for different phenotypes? |
| cord-012010-5h2ox3hu | Not so Atypical Is a"Cytokine Storm"Relevant to COVID-19? |
| cord-012010-5h2ox3hu | Toward Smarter Lumping and Smarter Splitting: Rethinking Strategies for Sepsis and Acute Respiratory Distress Syndrome Clinical Trial Design Management of COVID-19 Respiratory Distress COVID-19-associated acute respiratory distress syndrome: is a different approach to management warranted? |
| cord-012010-5h2ox3hu | cord-012010- 5h2ox3hu authors: Bos, Lieuwe D.J.; Sinha, Pratik; Dickson, Robert P. title: Response to “ COVID-19 conundrum: Clinical phenotyping based on pathophysiology as a promising approach to guide therapy in a novel illness ” and “ Strengthening the foundation of the house of CARDS by phenotyping on the fly ” and “ COVID-19 phenotypes: leading or misleading? ” |
| cord-327169-sz4ildnd | Practice Statement from an International Expert Panel Bronchoscopy to assess patients with hemoptysis: which is the optimal timing? |
| cord-325565-cz9f65ca | [ 3, 5, 16] It is important to ask why is this the way COVID-19 air pollution research is being reviewed and communicated? |
| cord-322580-7ohso8hl | lessons from tuberculosis for the COVID-19 response Quesiti scientifici relativi all'infezione da Coronavirus SARS- CoV-2 A role for CT in COVID-19? |
| cord-322075-e6whegrf | What Other Countries Can Learn From Italy During the COVID-19 Pandemic Cassandra's curse and covid-19: why do governments listen to businesses over doctors? |
| cord-322075-e6whegrf | what next? |
| cord-296694-2js639bk | COVID-19 milieu? |
| cord-296694-2js639bk | Can this be done using D- dimer alone and what is the threshold to use? |
| cord-296694-2js639bk | One obvious question is whether these rates of thrombosis are higher than we would expect? |
| cord-296694-2js639bk | What do you do with patients when they are discharged? |
| cord-296694-2js639bk | With regards to non- ICU patients, questions to be asked include: what are the triggers for more intense anticoagulation where imaging is not available? |
| cord-275858-46jzw94p | How can we manipulate the unique airway pathology of COPD patients and the ACE-2 system to identify novel therapeutics? |
| cord-275858-46jzw94p | Is telerehabilitation a safe and viable option for patients with COPD? |
| cord-275858-46jzw94p | Prevalence, severity and mortality associated with COPD and smoking in patients with COVID-19: a rapid systematic review and meta- analysis Angiotensin- converting enzyme 2 is a functional receptor for the SARS coronavirus SARS- CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor Functional assessment of cell entry and receptor usage for SARS- CoV-2 and other lineage B betacoronaviruses Structure, Function, and Antigenicity of the SARS- CoV-2 Spike Glycoprotein A pneumonia outbreak associated with a new coronavirus of probable bat origin ACE-2 Expression in the small airway epithelia of smokers and COPD patients: implications for COVID-19 Tobacco smoking increases the lung gene expression of ACE2, the receptor of SARS- CoV-2 Assessing ACE2 expression patterns in lung tissues in the pathogenesis of COVID-19 Expression of the SARS- CoV-2 ACE2 receptor in the human airway epithelium COVID-19 and nicotine as a mediator of ACE-2 COVID-19 and smoking: is nicotine the hidden link? |
| cord-275858-46jzw94p | What can we learn from the experience of virtual care to COPD patients during this pandemic that can be applied in future scenarios to reach isolated patient populations and resource limited settings? |
| cord-275858-46jzw94p | What is the role of inhaled substances( e.g. tobacco, cannabis and e- cigarettes) and air pollution in increasing the susceptibility of COPD patients to COVID-19? |
| cord-275858-46jzw94p | What will the impact of post- COVID-19 infection disability be in COPD patients and what resources will be required to adequately support the transition of COPD patients from the hospital to home after COVID-19? |
| cord-275858-46jzw94p | does COVID-19 infection in each of these phenotypes present and behave differently? |
| cord-275858-46jzw94p | if so, how? |
| cord-275858-46jzw94p | • Are routine medications used in COPD such as inhaled and systemic corticosteroids, β 2-agonists, muscarinic antagonists and chronic azithromycin protective or harmful in the setting of COVID-19 infection? |
| cord-338351-y1t9emu1 | Ora, Josuel; Puxeddu, Ermanno; Cavalli, Francesco; Giorgino, Federica Maria; Girolami, Andrea; Chiocchi, Marcello; Sergiacomi, Giaunluigi; Federici, Massimo; Rogliani, Paola title: Does bronchoscopy help the diagnosis in Covid-19 infection? |
| cord-344641-rog2h4g7 | what next? |
| cord-330093-asba80bi | ACE-2 expression in the small airway epithelia of smokers and COPD patients: implications for COVID-19 COVID-19 and smoking: is nicotine the hidden link? |
| cord-330093-asba80bi | COVID-19 and nicotine as a mediator of ACE-2 Systematic review of the prevalence of current smoking among hospitalized COVID-19 patients in China: could nicotine be a therapeutic option? |
| cord-330093-asba80bi | COVID-19 and vaping: risk for increased susceptibility to SARS- CoV-2 infection? |
| cord-330093-asba80bi | statista.com/statistics/673619/smoking-prevalence-among-men-us-by-age/ Date last accessed COVID-19 and smoking: is nicotine the hidden link? |
| cord-339934-g6ufz29l | COVID-19 pneumonia: a random association? |
| cord-351407-7vx9lzi0 | COVID-19 and its implications for thrombosis and anticoagulation Pulmonary embolism in patients with Covid-19 pneumonia Venous thromboembolism in SARS- CoV-2 patients: only a problem in ventilated ICU patients, or is there more to it? |
| cord-351407-7vx9lzi0 | The emerging safety profile of JAK inhibitors in rheumatic disease Thromboembolism with Janus Kinase( JAK) Inhibitors for Rheumatoid Arthritis: How Real is the Risk? |
| cord-349440-jxigsdzh | COVID-19 phenotypes: leading or misleading? |
| cord-349440-jxigsdzh | The perils of premature phenotyping in COVID: a call for caution COVID-19 pneumonia: different respiratory treatments for different phenotypes? |
| cord-350166-loxe11d6 | As change accelerates, how can medtechs move ahead and stay there? |
| cord-347046-u764muk6 | Did Europe recover because sumer is icumen in? |
| cord-347046-u764muk6 | They assume the current fall in the rate of COVID-19 related mortality is a consequence of lockdown; but is it? |
| cord-335198-qp964238 | And how do we quickly establish and conduct difficult and costly randomized, controlled clinical trials for the most promising old and new therapies where there is a clear equipoise between possible benefits and potential risks? |
| cord-335198-qp964238 | But how do we minimize the risks of progression in more severe hospitalized cases, particularly older patients with risk factor co- morbidities? |
| cord-335198-qp964238 | How did we rapidly implement a convalescent plasma program? |
| cord-335198-qp964238 | How do we best explore and exploit our overall clinical management and scientific research approach during the COVID19 pandemic? |
| cord-335198-qp964238 | How do we maximize compassionate use of available, potentially useful but unproven therapies when no other alternatives exist? |
| cord-335198-qp964238 | How do we minimize the risks of these very same therapies for individual patients? |
| cord-335198-qp964238 | How many patients? |
| cord-335198-qp964238 | How to adjust for confounder variables? |
| cord-335198-qp964238 | What disease severity? |
| cord-335198-qp964238 | What dose? |
| cord-335198-qp964238 | What to measure?, and how?, and why? |
| cord-335198-qp964238 | What to measure?, and how?, and why? |
| cord-335198-qp964238 | What to measure?, and how?, and why? |
| cord-335198-qp964238 | Which drugs to trial? |
| cord-335198-qp964238 | Which endpoints? |
| cord-335198-qp964238 | Which patients? |
| cord-335198-qp964238 | Whose needs are being met? |
| cord-335198-qp964238 | Why have n't others delivered more results? |